TNFRSF10A and non-Hodgkin lymphoma: TRAIL-R1 monoclonal antibody (Mapatumumab) is in phase-II clinical trials for relapsed or refractory Non-Hodgkin's Lymphoma (NHL) as monotherapy and for multiple myeloma as combination therapy with Bortezomib.